

FORM D

Notice of Exempt  
Offering of Securities

UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C.

OMB APPROVAL

OMB Number: 3235-0076

Estimated Average burden hours  
per response: 4.0

1. Issuer's Identity

CIK (Filer ID Number)

Previous Name(s)

☐ None

Entity Type

0001795091

OS THERAPIES Inc

☒ Corporation

☐ Limited Partnership

☐ Limited Liability Company

☐ General Partnership

☐ Business Trust

☐ Other

Name of Issuer

OS Therapies Inc

Jurisdiction of  
Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

☒ Over Five Years Ago

☐ Within Last Five Years  
(Specify Year)

☐ Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

OS Therapies Inc

Street Address 1

Street Address 2

115 Pullman Crossing Road

Suite #103

City

State/Province/Country

ZIP/Postal Code

Phone No. of Issuer

Grasonville

MARYLAND

21638

(410) 297-7793

3. Related Persons

Last Name

First Name

Middle Name

Romness

Paul

A.

Street Address 1

Street Address 2

115 Pullman Crossing Road

Suite #103

City

State/Province/Country

ZIP/Postal Code

Grasonville

MARYLAND

21638

Relationship:

☒ Executive Officer

☒ Director

☐ Promoter

Clarification of Response (if Necessary)

Founder, Chairman, President and Chief Executive Officer

Last Name

First Name

Middle Name

Petit

Robert

G.

Street Address 1

Street Address 2

115 Pullman Crossing Road

Suite #103

City

State/Province/Country

ZIP/Postal Code

Grasonville

MARYLAND

21638

|               |                                                       |                                   |                                   |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|
| Relationship: | <input checked="" type="checkbox"/> Executive Officer | <input type="checkbox"/> Director | <input type="checkbox"/> Promoter |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|

Clarification of Response (if Necessary)

Chief Medical Officer and Chief Scientific Officer

|           |             |             |
|-----------|-------------|-------------|
| Last Name | First Name  | Middle Name |
| Acevedo   | Christopher | P.          |

|                           |                        |                 |
|---------------------------|------------------------|-----------------|
| Street Address 1          | Street Address 2       |                 |
| 115 Pullman Crossing Road | Suite #103             |                 |
| City                      | State/Province/Country | ZIP/Postal Code |
| Grasonville               | MARYLAND               | 21638           |

|               |                                                       |                                   |                                   |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|
| Relationship: | <input checked="" type="checkbox"/> Executive Officer | <input type="checkbox"/> Director | <input type="checkbox"/> Promoter |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|

Clarification of Response (if Necessary)

Chief Financial Officer

|             |            |             |
|-------------|------------|-------------|
| Last Name   | First Name | Middle Name |
| Commissiong | Gerald     |             |

|                           |                        |                 |
|---------------------------|------------------------|-----------------|
| Street Address 1          | Street Address 2       |                 |
| 115 Pullman Crossing Road | Suite #103             |                 |
| City                      | State/Province/Country | ZIP/Postal Code |
| Grasonville               | MARYLAND               | 21638           |

|               |                                                       |                                   |                                   |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|
| Relationship: | <input checked="" type="checkbox"/> Executive Officer | <input type="checkbox"/> Director | <input type="checkbox"/> Promoter |
|---------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|

Clarification of Response (if Necessary)

Chief Business Officer

|           |            |             |
|-----------|------------|-------------|
| Last Name | First Name | Middle Name |
| Ciccio    | John       |             |

|                           |                        |                 |
|---------------------------|------------------------|-----------------|
| Street Address 1          | Street Address 2       |                 |
| 115 Pullman Crossing Road | Suite #103             |                 |
| City                      | State/Province/Country | ZIP/Postal Code |
| Grasonville               | MARYLAND               | 21638           |

|               |                                            |                                              |                                   |
|---------------|--------------------------------------------|----------------------------------------------|-----------------------------------|
| Relationship: | <input type="checkbox"/> Executive Officer | <input checked="" type="checkbox"/> Director | <input type="checkbox"/> Promoter |
|---------------|--------------------------------------------|----------------------------------------------|-----------------------------------|

Clarification of Response (if Necessary)

|               |            |             |
|---------------|------------|-------------|
| Last Name     | First Name | Middle Name |
| McKean Dieser | Avril      |             |

|                           |                        |                 |
|---------------------------|------------------------|-----------------|
| Street Address 1          | Street Address 2       |                 |
| 115 Pullman Crossing Road | Suite #103             |                 |
| City                      | State/Province/Country | ZIP/Postal Code |
| Grasonville               | MARYLAND               | 21638           |

Clarification of Response (if Necessary)

Clarification of Response (if Necessary)

Clarification of Response (if Necessary)

**Revenue Range** **Aggregate Net Asset Value Range**

- |                                                      |                                                    |
|------------------------------------------------------|----------------------------------------------------|
| <input type="radio"/> No Revenues                    | <input type="radio"/> No Aggregate Net Asset Value |
| <input type="radio"/> \$1 - \$1,000,000              | <input type="radio"/> \$1 - \$5,000,000            |
| <input type="radio"/> \$1,000,001 - \$5,000,000      | <input type="radio"/> \$5,000,001 - \$25,000,000   |
| <input type="radio"/> \$5,000,001 - \$25,000,000     | <input type="radio"/> \$25,000,001 - \$50,000,000  |
| <input type="radio"/> \$25,000,001 - \$100,000,000   | <input type="radio"/> \$50,000,001 - \$100,000,000 |
| <input type="radio"/> Over \$100,000,000             | <input type="radio"/> Over \$100,000,000           |
| <input checked="" type="radio"/> Decline to Disclose | <input type="radio"/> Decline to Disclose          |
| <input type="radio"/> Not Applicable                 | <input type="radio"/> Not Applicable               |

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- |                                                                  |                                                              |
|------------------------------------------------------------------|--------------------------------------------------------------|
| <input type="checkbox"/> Rule 504(b)(1) (not (i), (ii) or (iii)) | <input checked="" type="checkbox"/> Rule 506(b)              |
| <input type="checkbox"/> Rule 504 (b)(1)(i)                      | <input type="checkbox"/> Rule 506(c)                         |
| <input type="checkbox"/> Rule 504 (b)(1)(ii)                     | <input type="checkbox"/> Securities Act Section 4(a) (5)     |
| <input type="checkbox"/> Rule 504 (b)(1)(iii)                    | <input type="checkbox"/> Investment Company Act Section 3(c) |

## 7. Type of Filing

- |                                                |                    |                                         |                                                  |
|------------------------------------------------|--------------------|-----------------------------------------|--------------------------------------------------|
| <input checked="" type="checkbox"/> New Notice | Date of First Sale | <input type="text" value="2024-12-31"/> | <input type="checkbox"/> First Sale Yet to Occur |
| <input type="checkbox"/> Amendment             |                    |                                         |                                                  |

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☐ Yes ☒ No

## 9. Type(s) of Securities Offered (select all that apply)

- |                                                                                                                                 |                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Pooled Investment Fund Interests                                                                       | <input checked="" type="checkbox"/> Equity                                                     |
| <input type="checkbox"/> Tenant-in-Common Securities                                                                            | <input type="checkbox"/> Debt                                                                  |
| <input type="checkbox"/> Mineral Property Securities                                                                            | <input checked="" type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security |
| <input checked="" type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | <input type="checkbox"/> Other (describe)                                                      |

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary)

## 11. Minimum Investment

Minimum investment accepted from any outside investor \$  USD

## 12. Sales Compensation

|                                                        |                                          |                               |
|--------------------------------------------------------|------------------------------------------|-------------------------------|
| Recipient                                              | Recipient CRD Number                     | <input type="checkbox"/> None |
| <input type="text" value="Brookline Capital Markets"/> | <input type="text" value="44656"/>       |                               |
| (Associated) Broker or Dealer                          | (Associated) Broker or Dealer CRD Number | <input type="checkbox"/> None |
| <input type="text" value="Arcadia Securities, LLC"/>   | <input type="text" value="44656"/>       |                               |

Street Address 1

Street Address 2

600 Lexington Avenue

30th Floor

City

State/Province/Country

ZIP/Postal Code

New York

NEW YORK

10022

State(s) of Solicitation

☐ All States

☐ Foreign/Non-US

- ALABAMA
- CALIFORNIA
- FLORIDA
- GEORGIA
- IDAHO
- ILLINOIS
- LOUISIANA
- MARYLAND
- MINNESOTA
- NEVADA
- NEW JERSEY
- NEW YORK
- TEXAS
- VIRGINIA
- WASHINGTON
- WISCONSIN
- WYOMING

Recipient

Recipient CRD Number

☐ None

Ceros Financial Services, Inc.

37869

(Associated) Broker or Dealer

☒ None

(Associated) Broker or Dealer CRD Number

☒ None

Street Address 1

Street Address 2

1445 Research Blvd.

Suite 530

City

State/Province/Country

ZIP/Postal Code

Rockville

MARYLAND

20850

State(s) of Solicitation

☐ All States

☐ Foreign/Non-US

ALABAMA

CALIFORNIA

FLORIDA

GEORGIA

IDAHO

ILLINOIS

LOUISIANA

MARYLAND

MINNESOTA

NEVADA

NEW JERSEY

NEW YORK

TEXAS

VIRGINIA

WASHINGTON

WISCONSIN

WYOMING

13. Offering and Sales Amounts

Total Offering Amount

\$1000000

USD

☐ Indefinite

Total Amount Sold

\$7103000

USD

Total Remaining to be Sold

\$2897000

USD

☐ Indefinite

Clarification of Response (if Necessary)

After selling \$7,103,000 in the Offering, the Issuer has determined to close the Offering.

14. Investors

☐

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

34

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions

\$240000

USD

☒ Estimate

Finders' Fees

\$0

USD

☐ Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$

0

USD

☐ Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

■

Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.

■

Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

■

Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer           | Signature          | Name of Signer  | Title                   | Date       |
|------------------|--------------------|-----------------|-------------------------|------------|
| OS Therapies Inc | /s/Paul A. Romness | Paul A. Romness | Chief Executive Officer | 2025-01-21 |